TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03949543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Lunch Intervention
Description: Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Lunch Intervention
Description: Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Dinner Intervention
Description: Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Dinner Intervention
Description: Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
Study: NCT00728936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: saline placebo given subcutaneously
Study: NCT00438464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Undergo prostatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT04301583

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: procyanidin B2 enriched cocoa
Description: Volunteers will intake 5 grams per day of dietary supplement for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: procyanidin B2 enriched cocoa
Description: Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
Study: NCT00132314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM risperidone
Description: long-acting injectable risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral antipsychotic medication
Description: doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
Study: NCT03822702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
Study: NCT02394418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Treatment of delirium by inhaled sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Treatment of delirium by propofol i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Treatment of delirium by dexmedetomidine i.v. infusion
Study: NCT02911818

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMS-recommended lifestyle counseling
Description: 21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMS-recommended lifestyle counseling
Description: 21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
Study: NCT02574559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Based Compassion Training Session: Developing Affection and Empathy
Description: Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion
Description: Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Based Compassion Training Session: Realizing Active Compassion
Description: Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Session
Description: 20 minute session completed weekly after the Cognitive Training Session
Study: NCT02911818

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMS-recommended lifestyle counseling
Description: 21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
Study: NCT03644810

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PPT measurement
Description: The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PPT measurement
Description: The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain catastrophizing scale
Description: A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain catastrophizing scale
Description: A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test
Description: The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test
Description: The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
Study: NCT02911818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 3.0mg
Description: Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 3.0mg
Description: Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 3.0mg
Description: Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 3.0mg
Description: Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Portion-Controlled Diet
Description: A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 15 MG

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extension Study CMS-recommended lifestyle counseling
Description: 4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extension Study CMS-recommended lifestyle counseling
Description: 4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
Study: NCT05325398

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
Description: The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)
Study: NCT03457610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and language intervention
Description: Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
Study: NCT04125329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
Study: NCT02018029

Intervention type: OTHER
Intervention: cardiac resynchronisation therapy
Study: NCT01943188

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study: NCT01506934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linifanib
Description: Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)
Study: NCT01306500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Description: 8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
Study: NCT04405921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: orally or via gastric tube
Study: NCT01943188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Undergo autologous PBMC infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02677532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter placement
Description: Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound infusion catheters placement
Description: Pre-peritoneal placement of two catheters for wound infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plus sufentanil epidural infusion
Description: Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
Study: NCT01009918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coreg CR®
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02677532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine wound infusion
Description: Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
Study: NCT02139332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFR Group
Description: The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
Study: NCT03263065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bran
Description: 220g rice pudding meal with raspberry jam with added bran flakes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nopal
Description: 220g rice pudding meal with raspberry jam with added nopal flakes
Study: NCT02139332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource & Referral Group
Description: The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc...), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
Study: NCT02981121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet remedies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT02320240

Intervention type: DRUG
Intervention: Duloxetine
Description: Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Venlafaxine
Description: Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Desvenlafaxine
Description: Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Citalopram
Description: Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Escitalopram
Description: Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Fluoxetine
Description: Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Fluvoxamine
Description: Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Paroxetine
Description: Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.

Intervention type: DRUG
Intervention: Sertraline
Description: Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Study: NCT04229069

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: alkaline salt mixture
Description: blood and tissue alkalinisation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no blood and tissue alkalinisation
Study: NCT03422640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Open label treatment with apremilast
Study: NCT03384004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrigation Technique 1
Description: Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrigation Technique 2
Description: Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
Study: NCT00105755

Intervention type: DEVICE
Group type: OTHER
Intervention: personal dermal thermometer (DT)

Intervention type: DEVICE
Group type: OTHER
Intervention: Device
Study: NCT00092677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: Duration of Treatment: 4 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: matching Placebo
Study: NCT03472040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: BCX7353 mg oral capsules administered once daily
Study: NCT02902822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-dermatology
Description: The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year.
Study: NCT04568187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeltiq
Description: Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: radiofrequency with 3000 Hz